Video
Dr. Tagawa on Updated Results of TAXYNERGY Trial in Prostate Cancer
Author(s):
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
Scott T. Tagawa, MD, Weill Cornell Medicine, discusses the updated results of a prospective biomarker anaylsis from the TAXYNERGY trial in patients with metastatic castration-resistant prostate cancer (mCRPC).
In TAXYNERGY, patients with mCRPC who were chemonaïve were randomized to either first-line docetaxel or cabazitaxel. After 4 cycles of treatment, if a ≥ 30% PSA decline was not achieved, patients switched to the alternative taxane.
Taxane sensitivity and resistance was evaluated. Through the use of circulating tumor cells, a real-time analysis of AR nuclear localization and MT stablization was performed to predict taxane sensitivity.
According to Tagawa, taxane-induced shifts in AR nuclear localization and MT stabilization may serve as an early biomarker.
